Thijn Brummelkamp

Thijn received his PhD from the Netherlands Cancer Institute (cum laude) and was appointed as a Fellow in 2004 at the Whitehead Institute for Biomedical Research in Cambridge in the United States. He was listed among the world’s top innovators under the age of 35 by M.I.T.’s Technology Review Magazine (2005) and was awarded the prestigious EMBO Gold Medal (2013). Thijn currently is a group leader at The Netherlands Cancer Institute, Professor of Experimental Genetics at Utrecht University and Adjunct PI at the Research Center for Molecular Medicine (CeMM) in Vienna. Thijn is also a co-founder of Haplogen GmbH and a member of their Scientific Advisory Board.